Trial Search Results
Assessment of 3D Transperineal Ultrasound Imaging w/ Matrix Array Transducers in Prostate Radiotherapy
SPECIFIC STUDY AIMS
1. To evaluate congruence between pelvic anatomical structures segmented on MRI and/or CT scans co-registered with transperineal US scans acquired with an optically and/or electromagnetically tracked matrix array ultrasound transducer.
2. To estimate the achievable accuracy of anatomy tracking based on 3D US matrix-array transducer imaging and grey-level based image registration algorithms.
Stanford is currently not accepting patients for this trial.
Collaborator: Philips Healthcare
- Men that will undergo prostate radiotherapy as a primary treatment or
- Age 18 or older
- Ability to understand and sign informed consent
- Younger than 18 yrs old
- Inability to provide written and spoken consent.
- Patients with implanted actively controlled devices that may be subject to
electromagnetic interference from the UroNav/PervuNav electromagnetic tracking used in
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study